Memantin Viatris

Memantine Hydrochloride, the active ingredient in Memantin Viatris, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is employed to treat cognitive decline associated with Alzheimer’s disease in adult patients.

GNH USA supplies Memantin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics, comprehensive documentation, and responsive technical support throughout the procurement process.

Memantin Viatris is used in the management of neurodegenerative conditions that involve glutamatergic excitotoxicity, primarily Alzheimer’s disease.

Alzheimer’s disease (moderate to severe): improves cognition, daily functioning, and behavioral symptoms in affected patients.

Memantin Viatris may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Dizziness: transient sensation of light‑headedness or imbalance. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness or lack of energy.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Psychosis or hallucinations: emergence of delusional thoughts or visual disturbances.

When prescribing Memantin Viatris, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose or monitor renal function because the drug is excreted unchanged in urine. - Concomitant NMDA antagonists: avoid combined use to prevent additive neuro‑psychiatric effects. - History of seizures: use with caution as memantine may lower seizure threshold. - Cardiovascular disease: monitor blood pressure as hypertension has been reported. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Memantin Viatris can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neuro‑psychiatric adverse events. - Cimetidine or other strong renal tubular secretion inhibitors: may raise memantine plasma levels. - High‑dose anticholinesterases (e.g., donepezil): may reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - Other CNS depressants (benzodiazepines, opioids): may enhance dizziness or sedation. - Antihypertensive agents: monitor blood pressure as memantine can cause hypertension. - Diuretics affecting renal clearance: adjust monitoring of renal function.